Recent positive late-stage trial results for the Merck-Moderna personalized mRNA cancer vaccine (intismeran autogene) combined with Keytruda have reinforced their established licensing and joint-development agreement, with shared costs and profits already in place. These clinical milestones, including sustained five-year recurrence-free survival benefits reported in 2026, support continued partnership without necessitating a full merger or acquisition. Merck’s significantly larger market capitalization, focus on internal pipeline expansion to offset the Keytruda patent cliff, and typical regulatory scrutiny for large pharma deals further weigh against transaction odds. Trader consensus at 80.5% for no announcement in 2026 reflects the absence of M&A filings, activist pressure, or strategic shifts amid favorable collaboration economics.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourOui
20% chance
NOUVEAU
NOUVEAU
31 déc. 2026
Oui
20% chance
NOUVEAU
NOUVEAU
31 déc. 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive late-stage trial results for the Merck-Moderna personalized mRNA cancer vaccine (intismeran autogene) combined with Keytruda have reinforced their established licensing and joint-development agreement, with shared costs and profits already in place. These clinical milestones, including sustained five-year recurrence-free survival benefits reported in 2026, support continued partnership without necessitating a full merger or acquisition. Merck’s significantly larger market capitalization, focus on internal pipeline expansion to offset the Keytruda patent cliff, and typical regulatory scrutiny for large pharma deals further weigh against transaction odds. Trader consensus at 80.5% for no announcement in 2026 reflects the absence of M&A filings, activist pressure, or strategic shifts amid favorable collaboration economics.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Marché ouvert : Aug 19, 2026, 3:58 PM ET
Volume
$20Date de fin
31 déc. 2026Marché ouvert
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive late-stage trial results for the Merck-Moderna personalized mRNA cancer vaccine (intismeran autogene) combined with Keytruda have reinforced their established licensing and joint-development agreement, with shared costs and profits already in place. These clinical milestones, including sustained five-year recurrence-free survival benefits reported in 2026, support continued partnership without necessitating a full merger or acquisition. Merck’s significantly larger market capitalization, focus on internal pipeline expansion to offset the Keytruda patent cliff, and typical regulatory scrutiny for large pharma deals further weigh against transaction odds. Trader consensus at 80.5% for no announcement in 2026 reflects the absence of M&A filings, activist pressure, or strategic shifts amid favorable collaboration economics.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$20Date de fin
31 déc. 2026Marché ouvert
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Recent positive late-stage trial results for the Merck-Moderna personalized mRNA cancer vaccine (intismeran autogene) combined with Keytruda have reinforced their established licensing and joint-development agreement, with shared costs and profits already in place. These clinical milestones, including sustained five-year recurrence-free survival benefits reported in 2026, support continued partnership without necessitating a full merger or acquisition. Merck’s significantly larger market capitalization, focus on internal pipeline expansion to offset the Keytruda patent cliff, and typical regulatory scrutiny for large pharma deals further weigh against transaction odds. Trader consensus at 80.5% for no announcement in 2026 reflects the absence of M&A filings, activist pressure, or strategic shifts amid favorable collaboration economics.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes